Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major.
作者信息
Casu Carla, Presti Vania Lo, Oikonomidou Paraskevi Rea, Melchiori Luca, Abdulmalik Osheiza, Ramos Pedro, Rivella Stefano
机构信息
Department of Pediatrics, Division of Hematology, Children's Hospital of Philadelphia (CHOP), PA, USA.
Penteli's Children's Hospital, Pediatric Department, Athens, Greece.
出版信息
Haematologica. 2018 Feb;103(2):e46-e49. doi: 10.3324/haematol.2017.181511. Epub 2017 Nov 2.
Abstract
摘要
相似文献
1
Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major.短期给予JAK2抑制剂可减轻中间型和重型β地中海贫血小鼠模型的脾肿大。
Haematologica. 2018 Feb;103(2):e46-e49. doi: 10.3324/haematol.2017.181511. Epub 2017 Nov 2.
2
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704.
3
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704.
4
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704.
5
Janus kinase 2 inhibitors in myeloproliferative disorders.Janus 激酶 2 抑制剂在骨髓增殖性疾病中的应用。
Expert Opin Investig Drugs. 2011 Jan;20(1):41-59. doi: 10.1517/13543784.2011.538382. Epub 2010 Dec 4.
6
[Current management of thalassemia intermedia].[中间型地中海贫血的当前管理]
Transfus Clin Biol. 2014 Nov;21(4-5):143-9. doi: 10.1016/j.tracli.2014.07.005. Epub 2014 Oct 2.
7
Hypothesis: how do JAK2-inhibitors work in myelofibrosis.假设：JAK2抑制剂在骨髓纤维化中如何发挥作用。
Leuk Res. 2009 Sep;33(9):1156-7. doi: 10.1016/j.leukres.2009.04.011. Epub 2009 May 17.
8
A comprehensive review of pacritinib in myelofibrosis.帕西替尼治疗骨髓纤维化的综合综述。
Future Oncol. 2015;11(20):2819-30. doi: 10.2217/fon.15.200. Epub 2015 Sep 14.
9
Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition.重新思考 JAK2 抑制：探索更特异和通用的 Janus 激酶抑制策略。
Leukemia. 2017 May;31(5):1023-1038. doi: 10.1038/leu.2017.43. Epub 2017 Jan 25.
10
[JAK2 inhibitors in the treatment of myeloproliferative neoplasms].[JAK2抑制剂在骨髓增殖性肿瘤治疗中的应用]
Rinsho Ketsueki. 2012 Oct;53(10):1600-7.
引用本文的文献
1
Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis.新型潜在治疗药物可调节与红细胞生成缺陷相关疾病的铁代谢和红细胞生成。
Haematologica. 2023 Oct 1;108(10):2582-2593. doi: 10.3324/haematol.2023.283057.
2
Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.铁蛋白抑制剂 vamifeport 改善输血治疗β-地中海贫血小鼠模型中的无效红细胞生成。
Haematologica. 2023 Oct 1;108(10):2703-2714. doi: 10.3324/haematol.2022.282328.
3
Non-Transfusion-Dependent Thalassemia: A Panoramic Review.非输血依赖型地中海贫血症：全景综述。
Medicina (Kaunas). 2022 Oct 21;58(10):1496. doi: 10.3390/medicina58101496.
4
The Roles of Mitophagy and Autophagy in Ineffective Erythropoiesis in β-Thalassemia.自噬和线粒体自噬在β-地中海贫血无效造血中的作用。
Int J Mol Sci. 2022 Sep 16;23(18):10811. doi: 10.3390/ijms231810811.
5
Improving Ineffective Erythropoiesis in Thalassemia: A Hope on the Horizon.改善地中海贫血中无效红细胞生成：曙光在前。
Cureus. 2021 Oct 5;13(10):e18502. doi: 10.7759/cureus.18502. eCollection 2021 Oct.
6
Advancing the care of β-thalassaemia patients with novel therapies.推进新型疗法治疗β-地中海贫血患者。
Blood Transfus. 2022 Jan;20(1):78-88. doi: 10.2450/2021.0265-21. Epub 2021 Oct 21.
7
Innovative Treatments for Rare Anemias.罕见贫血的创新疗法。
Hemasphere. 2021 Jun 1;5(6):e576. doi: 10.1097/HS9.0000000000000576. eCollection 2021 Jun.
8
The Role of Iron in Benign and Malignant Hematopoiesis.铁在良性和恶性造血中的作用。
Antioxid Redox Signal. 2021 Aug 20;35(6):415-432. doi: 10.1089/ars.2020.8155. Epub 2021 Jan 7.
9
Heparanase Level and Procoagulant Activity Are Increased in Thalassemia and Attenuated by Janus Kinase 2 Inhibition.硫酸乙酰肝素酶水平和促凝血活性在地中海贫血中增加，并被 Janus 激酶 2 抑制所减弱。
Am J Pathol. 2020 Oct;190(10):2146-2154. doi: 10.1016/j.ajpath.2020.07.011. Epub 2020 Aug 1.
10
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.β-地中海贫血：除输血和铁螯合之外的新治疗选择。
Drugs. 2020 Jul;80(11):1053-1063. doi: 10.1007/s40265-020-01341-9.
本文引用的文献
1
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.小肝细胞生成素肽作为受β地中海贫血和真性红细胞增多症影响的小鼠的疾病修饰剂。
Blood. 2016 Jul 14;128(2):265-76. doi: 10.1182/blood-2015-10-676742. Epub 2016 May 6.
2
Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.芦可替尼治疗对骨髓纤维化患者血红蛋白动态变化及贫血不良预后的影响。
Leuk Lymphoma. 2016 Oct;57(10):2464-7. doi: 10.3109/10428194.2016.1146950. Epub 2016 Feb 25.
3
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.JAK2选择性抑制剂fedratinib治疗对骨髓纤维化患者骨髓纤维化的影响。
J Transl Med. 2015 Sep 10;13:294. doi: 10.1186/s12967-015-0644-4.
4
Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.骨髓增殖性肿瘤：作为治疗核心靶点的JAK2信号通路
Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S23-35. doi: 10.1016/j.clml.2014.06.014.
5
β-thalassemia intermedia: a clinical perspective.中间型β-地中海贫血：临床视角。
Cold Spring Harb Perspect Med. 2012 Jul;2(7):a013482. doi: 10.1101/cshperspect.a013482.
6
The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.无效红细胞生成在非输血依赖型地中海贫血中的作用。
Blood Rev. 2012 Apr;26 Suppl 1(0 1):S12-5. doi: 10.1016/S0268-960X(12)70005-X.
7
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.INCB018424，一种 JAK1 和 JAK2 抑制剂，在骨髓纤维化中的安全性和疗效。
N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.
8
9
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.选择性 JAK1/2 抑制剂 INCB018424 的临床前特征：治疗骨髓增生性肿瘤的治疗意义。
Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3.
10
Vascular complications after splenectomy for hematologic disorders.血液系统疾病脾切除术后的血管并发症。
Blood. 2009 Oct 1;114(14):2861-8. doi: 10.1182/blood-2009-04-210112. Epub 2009 Jul 27.
Zotero 插件